Aurora Spine Corporation Announces Co-Marketing Agreement for its DEXA Platform with Echolight Medical

CARLSBAD, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a manufacturer of innovative spinal implants announced today that it has entered into a joint co-marketing agreement with Echolight Medical, a manufacturer of the radiation-free EchoS portable densitometer used for patient assessment of bone mineral density (BMD) and the quality of bone microarchitecture independent of BMD.

Aurora is developing and manufacturing DEXA Technology-based Spinal Implants, and Echolight is engaged in the business of bone health assessment without the use of ionizing radiation. The two companies agreed to promote each other’s products as part of the Aurora DEXA Platform to their respective customers and prospects.

This mutual effort allows Aurora to combine Echolight’s bone health assessment capabilities with its proprietary DEXA Technology based patient matched implants and allows Echolight to market and promote Echolight’s devices to determine which of Aurora’s DEXA Technology implants is most appropriate for each patient’s bone quality, normal, osteopenic or osteoporotic.

Trent Northcutt, CEO and President at Aurora Spine said, “Aurora looks forward to working with Echolight and to offer comprehensive bone scanning capabilities with Aurora’s patient-matched DEXA Platform family of spinal implants. This joint effort will provide patients with a one-stop shop for patient matched implants based on quick and accurate real-time bone quality analysis with immediately available reports. We firmly believe that our partnership and shared passion will expand health care access to more people.”

Doug Tefft, President of Echolight Medical stated “We are pleased to contribute to Aurora’s innovative DEXA Platform. This allows Echolight to provide orthopedic and spinal treatment support in addition to bone health assessment for osteoporosis. Echolight devices are widely used in Europe and have recently been launched in the US.   Echolight expects significant clinical impact pairing its portable, radiation free devices in the United States with the only patented and FDA cleared bone quality matched fusion devices,” said Doug Tefft, President of Echolight USA. “It’s a privilege to join forces with the Aurora Team in the spinal and orthopedic fixation field.”

Laszlo Garamszegi, Chief Technology Officer of Aurora Spine added “Both companies received positive feedback from attendees at the 2022 Orthopedic Research Society meeting in Tampa that Aurora’s DEXA Technology and the Echolight REMS Technology work well together and complement each other in the bone quality diagnosis and treatment of patients with spinal conditions that require fusion surgery. We think that our mutual efforts with the Echolight Team will bring new solutions to the marketplace and elevate the standard of care for patients.”

About Echolight

Echolight Medical has developed the first clinically available method for the direct non-ionizing measurement of lumbar and femoral bone mineral density (BMD).

The device, EchoS, utilizes proprietary R.E.M.S. (Radiofrequency Echographic Multi Spectrometry) technology to scan the lumbar vertebrae and proximal femur. The EchoS rapidly generates a medical report that includes BMD, T-score and Z-score. In addition, the system automatically assesses the quality of bone micro architecture, independent of BMD, and provides a five-year probability of a major osteoporosis fracture.

EchoS offers significantly increased levels of accuracy, sensitivity to bone mass changes and diagnostic reproducibility over DXA systems. This, coupled with the absence of ionizing radiation, allows for osteoporosis diagnosis at the point of care more broadly and at an earlier stage. It also enables more accurate monitoring post diagnosis. Learn more about the FDA-cleared EchoS at: www.echolightmedical.com.